Morbidity of tamoxifen-perceptions of patients and healthcare professionals

被引:6
作者
Adlard, JW [1 ]
Campbell, J [1 ]
Bishop, JM [1 ]
Dodwell, DJ [1 ]
机构
[1] Cookridge Hosp, Yorkshire Reg Ctr Canc Treatment, Leeds LS16 6QB, W Yorkshire, England
关键词
D O I
10.1054/brst.2002.0418
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
There is little published data comparing patients' and doctors' perceptions of tamoxifen-related morbidity and toxicity, in particular in terms of side-effects which are not medically serious but which disrupt quality of life. We undertook a questionnaire-based study of 210 randomly selected, disease-free pre- and post-menopausal breast cancer patients to assess perceived morbidity whilst taking tamoxifen. We also questioned 143 healthcare professionals, including nurses, GPs and oncologists, on their opinions of tamoxifen-related side-effects. This study suggests that patients experience significant morbidity while taking adjuvant tamoxifen but will tolerate this for the sake of anticipated benefits. Healthcare professionals particularly hospital-based doctors and specialist nurses tend to overestimate the prevalence and severity of tamoxifen-associated symptoms. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:335 / 339
页数:5
相关论文
共 15 条
[1]
ABE O, 1992, LANCET, V339, P71
[2]
Abram P, 1996, J NATL CANCER I, V88, P1834
[3]
[Anonymous], 1992, Lancet, V339, P1
[4]
Risk and prognosis of endometrial cancer after tamoxifen for breast cancer [J].
Bergman, L ;
Beelen, MLR ;
Gallee, MPW ;
Hollema, H ;
Benraadt, J ;
van Leeuwen, FE .
LANCET, 2000, 356 (9233) :881-887
[5]
Reliability and validity of the functional assessment of cancer therapy-breast quality-of-life instrument [J].
Brady, MJ ;
Cella, DF ;
Mo, F ;
Bonomi, AE ;
Tulsky, DS ;
Lloyd, SR ;
Deasy, S ;
Cobleigh, M ;
Shiomoto, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :974-986
[6]
Clarke M, 1998, LANCET, V351, P1451
[7]
Adjuvant tamoxifen: Predictors of use, side effects, and discontinuation in older women [J].
Demissie, S ;
Silliman, RA ;
Lash, TL .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (02) :322-328
[8]
Fallowfield LJ, 1999, BREAST CANCER RES TR, V55, P189
[9]
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors [J].
Fisher, B ;
Dignam, J ;
Bryant, J ;
DeCillis, A ;
Wickerham, DL ;
Wolmark, N ;
Costantino, J ;
Redmond, C ;
Fisher, ER ;
Bowman, DM ;
Deschenes, L ;
Dimitrov, NV ;
Margolese, RG ;
Robidoux, A ;
Shibata, H ;
Terz, J ;
Paterson, AHG ;
Feldman, MI ;
Farrar, W ;
Evans, J ;
Lickley, HL .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1529-1542
[10]
A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484